Advancements in Abuse Potential Assessments 
- Building on the FDA Draft Guidance for Industry

Cross Company Abuse Liability Council

The Cross Company Abuse Liability Council (CCALC), formerly Cross Company Abuse Liability Consortium, was founded in 2006. 

The purpose of CCALC is to formulate and communicate scientific perspectives about medication abuse and its mitigation.  The mission of CCALC is to improve public health by advancing the science of assessing abuse liability and potential across the product life cycle to promulgate best practices by working with regulators, academic researchers, and public policy advocates.